Cargando…

Non-ergot dopamine agonists and heart failure

Detalles Bibliográficos
Autores principales:	Şener, Yusuf Ziya, Okşul, Metin, Çöteli, Cem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kare Publishing 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382895/ https://www.ncbi.nlm.nih.gov/pubmed/30587710 http://dx.doi.org/10.14744/AnatolJCardiol.2018.76299

Ejemplares similares

Left ventricular global longitudinal strain rate is influenced by stable coronary artery disease
por: Şener, Yusuf Ziya, et al.
Publicado: (2019)

Comment on “Pulmonary Function Tests in Hypertensive Patients Attending Zewditu Memorial Hospital, Addis Ababa, Ethiopia”
por: Şener, Yusuf Ziya, et al.
Publicado: (2019)

Factors associated with periprocedural myocardial infarction
por: Okşul, Metin, et al.
Publicado: (2019)

Effects of obstructive sleep apnea and atrial fibrillation on blood pressure variability
por: Şener, Yusuf Ziya, et al.
Publicado: (2019)

Effects of colchicine on cardiac functions
por: Şener, Yusuf Ziya, et al.
Publicado: (2019)

Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine
por: Clausen, Marianne F., et al.
Publicado: (2021)

Non-Ergot Dopamine Agonists Do Not Increase the Risk of Heart Failure in Parkinson’s Disease Patients: A Meta-Analysis of Randomized Controlled Trials
por: De Vecchis, Renato, et al.
Publicado: (2016)

Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson’s Disease
por: Jing, Xiao-Zhong, et al.
Publicado: (2023)

Risk factors for postoperative atrial fibrillation
por: Şener, Yusuf Z, et al.
Publicado: (2019)

Evaluation of the effect of non-ergot dopamine agonists on left ventricular systolic function with speckle tracking echocardiography
por: Pamukcu, Hilal Erken, et al.
Publicado: (2018)

Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey
por: Rizos, A., et al.
Publicado: (2020)

Efficacy and safety of non‐ergot dopamine‐receptor agonists as an adjunct to levodopa in advanced Parkinson's disease: A network meta‐analysis
por: Chen, Xiang‐Ting, et al.
Publicado: (2022)

Incidental Findings Diagnosed during Preprocedural Evaluation of TAVR
por: Sahiner, Levent, et al.
Publicado: (2019)

Long-term outcomes of left atrial appendage isolation using cryoballoon in persistent atrial fibrillation
por: Yorgun, Hikmet, et al.
Publicado: (2022)

Comparative efficacy and safety of six non-ergot dopamine-receptor agonists in early Parkinson's disease: a systematic review and network meta-analysis
por: Chen, Xiang-Ting, et al.
Publicado: (2023)

Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists
por: Ikeda, Ken, et al.
Publicado: (2016)

The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial(†)
por: Busso, Cristiano, et al.
Publicado: (2010)

Ergot
por: Smith, T. Curtis
Publicado: (1875)

Comments on: Relapse of acute lymphoblastic leukemia presenting as masquerade uveitis with hypopyon in a child
por: Evereklioglu, Cem, et al.
Publicado: (2023)

Response to comment on: Nasal vein occlusion after COVID-19: A case report
por: Güven, Yusuf Ziya, et al.
Publicado: (2023)

Heart failure with preserved ejection fraction: A distinct heart failure phenotype?
por: Triposkiadis, Filippos, et al.
Publicado: (2022)

Ergot of Rye
Publicado: (1831)

Ergot in Menorrhagia
Publicado: (1857)

Ergot of Wheat
Publicado: (1857)

Ergot in Dysentery
Publicado: (1874)

Ergot-Poisoning
por: Keating, John M.
Publicado: (1880)

The Comparative Efficacy of Non-ergot Dopamine Agonist and Potential Risk Factors for Motor Complications and Side Effects From NEDA Use in Early Parkinson's Disease: Evidence From Clinical Trials
por: Wu, Chunxiao, et al.
Publicado: (2022)

Cases of ergotism in livestock and associated ergot alkaloid concentrations in feed
por: Craig, A. Morrie, et al.
Publicado: (2015)

Invasive versus non-invasive hemodynamic monitoring of heart failure patients and their outcomes
por: Kandah, Fadi, et al.
Publicado: (2022)

Letter to the editor: Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: The contribution of previous heart failure to heart failure hospitalization may be overestimated
por: Mei, Kaibo, et al.
Publicado: (2023)

Ivabradine tolerability in heart failure
por: Birkhoelzer, Sarah, et al.
Publicado: (2018)

Heart Failure in a DGH
por: Cheng, Tsung O.
Publicado: (1993)

Endomyocardial biopsy in the hands of the electrophysiologist: the ‘one‐stop shop’ for arrhythmic non‐ischaemic cardiomyopathy. Letter regarding the article ‘Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy’
por: Compagnucci, Paolo, et al.
Publicado: (2021)

Medical Malpractice: Sight of the Physicians at the Gülhane Military Medical Academy
por: ÖZMEN, Pelin, et al.
Publicado: (2015)

Persistent ascites resolving with gonadotropin-releasing-hormone-agonist 18 months after hospitalization for severe ovarian hyperstimulation syndrome
por: Comba, Cihan, et al.
Publicado: (2013)

Mechanism of dopamine binding and allosteric modulation of the human D1 dopamine receptor
por: Zhuang, Youwen, et al.
Publicado: (2021)

Outcomes of the conservative management of the patients with endometrial intraepithelial neoplasia/endometrial cancer: Wait or treat!
por: İŞÇİ BOSTANCI, Esra, et al.
Publicado: (2022)

Analysis of Ergot Alkaloids
por: Crews, Colin
Publicado: (2015)

Ergot of Rye as an Oxytocic
por: Swayne, J. G.
Publicado: (1894)

Ergot of Rye in Leucorrhœa
Publicado: (1831)

Cannot write session to /tmp/vufind_sessions/sess_l2fs5invnlho6sv1sqi0lkdo5e